Organization | Agilent Technologies, Inc.

Agilent Technologies, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Santa Clara CA United States (1999)

Status: No NME R&D (1999)

Organization Overview

First Clinical Trial

2016

NCT02452697

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (5)

Key: Agilent Technologies, Inc. (0) Acquired (5)

cyclophosphamide (cytoxan) (1 trial)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (2 trials)

epirubicin (ellence) (1 trial)

memantine (namenda) (1 trial)

Drugs in Phase 2 Trials (10)

Key: Agilent Technologies, Inc. (2) Acquired (8)

allogeneic natural killer cells (1 trial)

carboplatin (paraplatin) (1 trial)

duk-cpg-001 (1 trial)

fludeoxyglucose f-18 (1 trial)

lutetium (177Lu) vipivotide tetraxetan (Pluvicto) (1 trial)

niraparib (zejula) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

pemetrexed (alimta) (1 trial)

(s)-4-(3-fluoropropyl)-l-glutamic acid (1 trial)

Drugs in Phase 1 Trials (3)

Key: Agilent Technologies, Inc. (0) Acquired (3)

alginic acid (1 trial)

pimonidazole (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 11
# of Trial APIs: 18